Document:

Exhibit 10.15

CODE OF CONDUCT

  
INTRODUCTION

  
It is the policy of Strategic Capital Resources, Inc. that our business shall be conducted in accordance with the highest moral, legal and ethical standards.  Our reputation for integrity is our most important asset and each employee and director must contribute to the care and preservation of that asset.

  
This reputation for integrity is the cornerstone of the public’s faith and trust in our Company; it is what provides us an opportunity to serve our investors, customers and other stakeholders.  A single individual’s misconduct can do much to damage a hard-earned reputation.  No code of business conduct or ethics can effectively substitute for the thoughtful behavior of an ethical director, officer or employee.  This Code of Conduct is presented to assist you in guiding your conduct to enhance the reputation of our Company.  The Code supersedes all previous codes and policy statements.

  The Code is drafted broadly.  In that respect, it is the Company’s intent to exceed the minimum requirements of the law and industry practice.  Mere compliance with the letter of the law is not sufficient to attain the highest ethical standards.  Good judgment and great care must also be exercised to comply with the SPIRIT of the law and of this Code.

  
The provisions of the Code apply to you, your spouse and members of your immediate family.  In addition, it covers any partnership, trust or other entity which you, your spouse or members of your immediate family control.

  
The Company intends to enforce the provisions of this Code vigorously.  Violations could lead to sanctions, including dismissal in the case of an employee, as well as, in some cases, civil and criminal liability.

  
Inevitably, the Code addresses questions and situations that escape easy definition.  No corporate code can cover every possible question of business practice.  There will be times when you are unsure about how the Code applies.  When in doubt, ask before you act.

  
Upholding the Code is the responsibility of every employee and director.  Department heads are responsible for Code enforcement in their departments and managers are accountable for the employees who report to them.

  
CONFLICTS OF INTEREST

  
The Company relies on the integrity and undivided loyalty of our employees and directors to maintain the highest level of objectivity in performing their duties.  Each employee is expected to avoid any situation in which your personal interests conflict, or have the appearance of conflicting, with those of the Company.  Individuals must not allow personal considerations or relationships to influence them in any way when representing the Company in business dealings.

  
A conflict situation can arise when an employee or director takes actions or has interests that may make it difficult to perform work on behalf of the Company objectively and effectively.  Conflicts also arise when an employee or director, or a member of his or her family, receives improper personal benefits as a result of his or her position with the Company.  Loans to, guarantees of obligations of, such persons are of special concern.

  All employees and directors must exercise great care any time their personal interests might conflict with those of the Company.  The APPEARANCE of a conflict often can be as damaging as an ACTUAL conflict.  PROMPT AND FULL DISCLOSURE IS ALWAYS THE CORRECT FIRST STEP TOWARDS IDENTIFYING AND RESOLVING ANY POTENTIAL CONFLICT OF INTEREST.  Non-employee directors are expected to make appropriate disclosures to the Board and to take appropriate steps to recuse themselves from Board decisions with respect to transactions or other matters involving the Company as to which they are interested parties or with respect to which a real or apparent conflict of interest exists.

  
The following sections review several common problems involving conflicts of interest.  The list is not exhaustive.  Each individual has a special responsibility to use his or her best judgment to assess objectively whether there might be even the appearance of acting for reasons other than to benefit the Company, and to discuss any conflict openly and candidly with the Company.

  
Payments and Gifts

  
Employees who deal with the Company’s borrowers, tenants, suppliers or other third parties are placed in a special position of trust and must exercise great care to preserve their independence.  As a general rule, no employee should ever receive a payment or anything of value in exchange for a decision involving the Company’s business.  Similarly, no employee of the Company should ever offer anything of value to government officials or others to obtain a particular result for the Company.  Bribery, kickbacks or other improper payments have no place in the Company’s business.

  
The Company recognizes exceptions for token gifts of nominal value (less than $250) or customary business entertainment when a clear business purpose is involved.  If you are in doubt about the policy’s application, we should be consulted.

  
Personal Financial Interests; Outside Business Interests

  
Employees should avoid any outside financial interests that might be in conflict with the interests of the Company.  No employee may have any significant direct or indirect financial interests in, or any business relationship with, a person or entity that does business with the Company or is a competitor of the Company.  A financial interest includes any interest as an owner, creditor or debtor.  Indirect interests include those through an immediate family member or other person acting on his or her behalf.  This policy does not apply to an employee’s arms-length purchases of goods or services for personal or family use, or to the ownership of shares in a publicly held corporation.

  Employees should not engage in outside jobs or other business activities that compete with the Company in any way.  Further, any outside or secondary employment (“moonlighting”) may interfere with the job being performed for the Company and is discouraged.  Under no circumstances may employees have outside interests that are in any way detrimental to the best interests of the Company.

  
You must disclose to us any personal activities or financial interests that could negatively influence, or give the appearance of negatively influencing, your judgment or decisions as a Company employee.  We will then determine if there is a conflict and, if so, how to resolve it without compromising the Company’s interest.

  
Corporate Boards

  
The director of an organization has access to sensitive information and charts the course of the entity.  If you are invited to serve as a director of an outside organization, the Company must take safeguards to shield both the Company and you from even the appearance of impropriety.  For that reason, any employee invited to join the Board of Directors of another organization (including a nonprofit or other charitable organization) must obtain our approval.  Directors who are invited to serve on other Boards should promptly notify the Chairman.

  
Corporate Opportunities

  
An employee or director must not divert for personal gain any business opportunity available to the Company.  The duty of loyalty to the Company is violated if the employee or director personally profits from a business opportunity that rightfully belongs to the Company.  This problem could arise, for example, if an employee or director becomes aware through the use of corporate property, information or position of an investment opportunity (either a loan or equity transaction) in which the Company is or may be interested, and then participates in the transaction personally or informs others of the opportunity before the Company has the chance to participate in the transaction.  An employee or director also is prohibited from using corporate property, information or position for personal gain.  Employees  and directors owe a duty to the Company to advance its legitimate interests when the opportunity to do so arises and, in the case of a
non-employee director, such director is aware of the Company’s possible interest through use of corporate property, information or position.

  USE AND PROTECTION OF COMPANY ASSETS

  
Proper use and protection of the Company’s assets is the responsibility of all employees.  Company facilities, materials, equipment, information and other assets should be used only for conducting the Company’s business and are not to be used for any unauthorized purpose.  Employees should guard against waste and abuse of Company assets in order to improve the Company’s productivity.

  
CONFIDENTIALITY

  
One of the Company’s most important assets is its confidential corporate information.  The Company’s legal obligations and its competitive position often mandate that this information remain confidential.

  
Confidential corporate information relating to the Company’s financial performance (e.g., quarterly financial results of the Company’s operations) or other transactions or events can have a significant impact on the value of the Company’s securities.  Premature or improper disclosure of such information may expose the individual involved to onerous civil and criminal penalties.

  
You must not disclose confidential corporate information to anyone outside the Company, except for a legitimate business purpose (such as contacts with the Company’s accountants or its outside lawyers).  Even with the Company, confidential corporate information should be discussed only with those who have a need to know the information.  Your obligation to safeguard confidential  corporate information continues even after you leave the Company.

  
The same rules apply to confidential information relating to other companies with which we do business.  In the course of the many pending or proposed transactions that this Company has under consideration at any given time, there is a great deal of non-public information relating to other companies to which our employees may have access.  This could include “material” information that is likely to affect the value of the securities of the other companies.

  Employees and directors who learn material information about suppliers, customers, venture partners, acquisition targets or competitors through their work at the Company must keep it confidential and must not buy or sell stock in such companies until after the information becomes public.  Employees and directors must not give tips about such companies to others who may buy or sell the stocks of such companies.

  DEALINGS WITH THE PRESS AND COMMUNICATIONS WITH THE PUBLIC

  The Company’s Chief Executive Officer and President are the Company’s principal spokesmen.  If someone outside the Company asks you questions or requests information regarding the Company, its business or financial results, do not attempt to answer.  All requests for information - from reporters, securities analysts, shareholders or the general public - should be referred to the President who will handle the request or delegate it to an appropriate person.<PAGE>

                                  EXHIBIT 10.87

                         PEREGRINE PHARMACEUTICALS, INC.

                                  COMMON STOCK
                               PURCHASE AGREEMENT

                               2,000,003 SHARES OF
                                  COMMON STOCK

                                  JUNE 6, 2003

<PAGE>

                         COMMON STOCK PURCHASE AGREEMENT
                         -------------------------------

         This Common Stock Purchase Agreement (this "Agreement") is made and
entered into as of June 6, 2003, by and between Peregrine Pharmaceuticals, Inc.,
a Delaware corporation (the "Company"), and the Investors set forth on Schedule
I hereto (each an "Investor", collectively, the "Investors").

                                    RECITALS
                                    --------

         WHEREAS, the Company has filed with the Securities and Exchange
Commission ("SEC") a Shelf Registration Statement on Form S-3 No. 333-103965,
which was declared effective by the SEC on March 31, 2003 (the "Form S-3").

         WHEREAS, pursuant to the Form S-3, the Company may offer to the public
from time to time up to 10,000,000 shares of common stock, par value $0.001 per
share (the "Common Stock").

         WHEREAS, the Company previously filed with the SEC a Shelf Registration
Statement on Form S-3 No. 333-71086 which was declared effective by the SEC on
November 14, 2001, pursuant to which the Company registered the offer of
10,000,000 shares of Common Stock, and Warrants to acquire 2,000,000 shares of
Common Stock (together with the underlying Common Stock to be issued upon
exercise thereof) (the "Warrant Form S-3);

         WHEREAS, the Company desires to sell and issue to the Investors under
the Form S-3 an aggregate of Two Million Three (2,000,003) shares of Common
Stock at the per share price of $0.86, and from the Warrant Form S-3 warrants
("Warrant") to purchase up to One Hundred Fifty Thousand (150,000) shares of
Common Stock at an exercise price of $0.86 per share ("Warrant Shares"), in
exchange for the Investors' payment of the sum of One Million Seven Hundred
Twenty Thousand Three Dollars ($1,720,003).

         NOW, THEREFORE, in consideration of the covenants, agreements and
considerations herein contained, the Company and Investor agree as follows:

1. PURCHASE AND SALE OF SHARES
------------------------------

         1.1 TRANSFER OF SHARES. Subject to the terms and conditions hereof, the
Company agrees to sell to the Investors, and the Investors agree to purchase
from the Company in the respective amounts set forth on Schedule I, an aggregate
of 2,000,003 shares of the Company's Common Stock (the "Shares"). On the Closing
Date, the Company shall instruct its transfer agent to transfer the Shares via
DWAC to each Investor, in the name of such Investor or its nominee, representing
the Shares purchased by such Investor.

         1.2 PURCHASE PRICE. As full consideration for the sale of the Shares to
Investors, the Investors shall deliver to the Company on the Closing Date by
wire transfer of immediately available funds to such account as the Company
shall designate the sum of One Million Seven Hundred Twenty Thousand Three
Dollars ($1,720,003) (the "Purchase Price"), representing a per share purchase
price of $0.86 per share (the "Per Share Price").

                                       1
<PAGE>

         1.3 WARRANTS. In connection with the Investors' purchase of the Shares,
the Company shall deliver to each Investor on the Closing Date a Warrant to
purchase a number of Warrant Shares equal to 7.5% of the Shares purchased,
exercisable on a cash basis only for a period of four (4) years, at an exercise
price equal to the Per Share Price, not to exceed warrants to purchase up to
150,000 shares of common stock.

2. CLOSING.
-----------

         2.1 TIME. Subject to terms and provisions herein, the purchase and sale
of the Shares and Warrants shall take place on June 6, 2003 (the "Closing Date")
at the offices of Falk, Shaff & Ziebell, LLP located at 18881 Von Karman Avenue,
Suite 1400, Irvine, California 92612, or such other location as the parties may
individually agree.

         2.2 DELIVERIES AT AND FOLLOWING THE CLOSING DATE. Upon the Company's
receipt of Purchase Price, the Company shall deliver all Shares, Warrants,
consents, assignments and other instruments and documents provided for in this
Agreement. In addition, the Company agrees to execute and deliver all
instruments and documents and perform all other acts which may be reasonably
required or appropriate in order to further effect or perfect the sale and
transfer of the Shares and the consummation of the transactions contemplated by
this Agreement.

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY
------------------------------------------------

         Except as set forth below, the Company makes no representations or
warranties of any nature or kind.

         3.1 ORGANIZATION, STANDING AND POWER. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware. The Company has the corporate power to own its properties and to carry
on its business as now being conducted and is duly qualified to do business and
is in good standing in each jurisdiction in which the failure to be so qualified
would have a material adverse effect on the business, assets or condition
(financial or otherwise) of the Company and its subsidiaries, taken as a whole.

         3.2 CAPITALIZATION. The authorized capital stock of the Company
consists of 175,000,000 shares of common stock, par value $0.001 per share, and
5,000,000 shares of preferred stock, par value $0.001 per share, of which, as of
June 2, 2003, there were approximately 121,359,000 shares of common stock and
nil shares of preferred stock, issued and outstanding. The Company is not a
party to any voting trust agreements or understandings with respect to the
voting common stock of the Company.

         3.3 AUTHORIZATION.

                  3.3.1 The Company has full legal right, power and capacity to
enter into, execute, deliver and perform this Agreement and all attendant
documents and instruments contemplated hereby.

                  3.3.2 This Agreement has been duly executed and delivered and
constitutes the legal, valid and binding obligation of the Company and is
enforceable with respect to the Company in accordance with its terms, except as
enforcement may be limited by bankruptcy, insolvency, priority or other laws or
court decisions relating to or affecting generally the enforcement of creditors'
rights or affecting generally the availability of equitable remedies.

                                       2
<PAGE>

                  3.3.3 The execution and delivery of this Agreement by the
Company, and the consummation of the transactions contemplated hereby by the
Company in accordance with the terms hereof shall not conflict with or result in
a breach of, violation of, or default under (or constitute an event that with
notice, lapse of time, or both, would constitute a breach or default under), or
result in the termination of, or accelerate the performance required by, or
result in the creation of any liens or other encumbrances upon any of the
properties or assets of the Company under any of the terms, conditions or
provisions of the Certificate of Incorporation or Bylaws, any provision of the
laws of the State of California or the State of Delaware, or any note, bond,
mortgage, indenture, deed of trust, license, lease, credit agreement or other
agreement, document, instrument or obligation to which the Company is a party or
by which any of its assets or properties are bound.

                  3.3.4 Neither the execution and delivery of this Agreement by
the Company, nor the consummation of the transactions, contemplated hereunder by
the Company will violate or conflict with any judgment, order, decree, statute,
rule or regulation applicable to the Company or its assets or properties.

         3.4 VALID ISSUANCE OF COMMON STOCK.

                  3.4.1 The Shares and Warrants being purchased by the Investor
hereunder and the Warrant Shares issuable upon exercise of the Warrants, when
issued, sold and delivered in accordance with the terms hereof or thereof, for
the consideration expressed herein or therein, will be duly and validly issued,
fully paid and nonassessable and will be issued in compliance with all
applicable federal and state securities laws.

                  3.4.2 The outstanding shares of Common Stock are all duly and
validly authorized and issued, fully paid and nonassessable, and were issued in
compliance with all applicable federal and state securities laws.

                  3.4.3 The Company has full power, right and authority to
transfer, convey and sell to the Investors on the Closing Date the Shares and
Warrants and upon consummation of the transactions contemplated by this
Agreement, each Investor will have acquired good and marketable title to the
Shares and Warrants purchased by such Investor, free and clear of claims, liens,
restrictions on transfer or voting or encumbrances.

         3.5 LITIGATION. Except as referred to in the SEC Documents, as defined
below, the Form S-3, or as disclosed in Schedule 3.5, there are no claims,
suits, actions or proceedings pending or, to the knowledge of the Company,
threatened against, relating to or affecting the Company or any of its
subsidiaries, before any court, governmental department, commission, agency,
instrumentality or authority, or any arbitrator that would reasonably be
expected, either alone or in the aggregate with all such claims, actions or
proceedings, to have a material adverse effect on the Company's business or
financial condition or the transactions contemplated hereunder. Except as
referred to in the Company's SEC Documents, neither the Company nor any of its
subsidiaries is subject to any judgment, decree, injunction, rule or order of
any court, governmental department, commission, agency, instrumentality or
authority, or any arbitrator which prohibits or restricts the consummation of
the transactions contemplated hereby or would have a material adverse effect on
the Company's business or financial condition or the transactions contemplated
hereunder.

                                       3
<PAGE>

         3.6 SEC DOCUMENTS; THE COMPANY'S FINANCIAL STATEMENTS. The Company is a
reporting company under the Securities Exchange Act of 1934 (the "Exchange
Act"), and files annual and periodic reports (the "SEC Documents") with the
Securities and Exchange Commission (the "SEC"). As of their respective filing
dates, the SEC Documents complied in all material respects with the requirements
of the Securities Exchange Act of 1934, as amended, applicable to the Company
and to the knowledge of the Company none of the SEC Documents contained any
untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary to make the statements made therein, in light
of the circumstances in which they were made, not misleading, except to the
extent corrected by a subsequently filed document with the SEC. The SEC
Documents contain an audited consolidated balance sheet of the Company as of the
end of the last completed fiscal year (the "Balance Sheet") and the related
audited consolidated statements of income and cash flow for the year then ended
(collectively, the "Financials"). The Financials have been prepared in
accordance with GAAP applied on a basis consistent through the periods indicated
and consistent with each other. The Financials present fairly the consolidated
financial condition and operating results and cash flows of the Company and its
subsidiaries as of the dates and during the periods indicated therein. Since the
date of the Balance Sheet and until the date of this Agreement, there has not
occurred any material adverse change in the business, assets or condition
(financial or otherwise) of the Company and its subsidiaries, taken as a whole,
which has not been reflected in the SEC Documents.

         3.7 FORM S-3. The Company has delivered to each Investor a copy of the
Form S-3 and Warrant Form S-3. The Company represents and warrants that each of
the Form S-3 and Warrant Form S-3 have been declared effective by the SEC and
neither is subject to any stop order. The Company is not aware of any event,
fact or circumstance which would cause the Form S-3 of Warrant Form S-3 to
contain a material misstatement. The Company at the time of the initial filing
of each of the Form S-3 and the Warrant Form S-3 met the SEC's eligibility
requirements for use of a Form S-3 in connection with a primary offering.

         3.8 DISCLOSURE. Neither this Agreement, nor any of the schedules,
attachments, or certificates attached to this Agreement or delivered by the
Company on the Closing Date, contains any untrue statements of material fact or
omits a material fact necessary to make the statements contained herein or
therein not misleading. There is no fact which the Company has not disclosed to
the Investors, orally or in writing, and of which any of the Company's directors
or officers are aware, which could reasonably be anticipated to have a material
adverse effect, upon the financial condition, operating results or assets, of
the Company. Notwithstanding the foregoing, certain information provided by the
Company to the Investors contained statements that are forward-looking, which
are covered by the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking information involves important risks
and uncertainties that could significantly affect anticipated results in the
future, and accordingly, such results may differ materially from those expressed
in any forward-looking statements made by or on behalf of the Company.

                                       4
<PAGE>

         3.9 REGULATORY COMPLIANCE. To the best of its knowledge, the Company is
not in violation of any applicable law, regulation, judgment, order or consent
decree (of any governmental or non-governmental regulatory or self-regulatory
agency or any organized exchange, including without limitation, the SEC, any
state or local securities or insurance regulatory body, or the Internal Revenue
Service), which violation is likely to have a material adverse effect on the
Company's business, financial condition, or this transaction.

         3.10 REGULATORY PROCEEDINGS, INVESTIGATIONS AND INQUIRIES. To the best
of its knowledge, the Company has not been the subject of any material
regulatory proceeding, examination, investigation or inquiry (known to the
Company), including any pending or threatened regulatory proceeding,
investigation or inquiry (known to the Company) (including without limitation
any by governmental or non-governmental regulatory or self-regulatory agency or
any organized exchange) relating to the Company.

         3.11 CERTAIN FEES. Except for fees or commissions payable by the
Company as set forth on Schedule A, no brokerage or finder's fees or commissions
are or will be payable by the Company to any broker, financial advisor or
consultant, finder, placement agent, investment banker, bank or other Person
with respect to the transaction contemplated by this Agreement. The Purchasers
shall have no obligation with respect to any fees or with respect to any claims
made by or on behalf of other Persons for fees of a type contemplated in this
Section that may be due in connection with the transactions contemplated by this
Agreement.

         3.12 REGISTRATION STATEMENT. The Company's Registration Statements on
Form S-3 (Nos. 333-71086 and 333-103965) (each a "Registration Statement") were
declared effective by the SEC on November 14, 2001 and March 31, 2002,
respectively. Each Registration Statement is effective on the date hereof and
the Company has not received notice that the SEC has issued or intends to issue
a stop order with respect to such Registration Statement or that the SEC
otherwise has suspended or withdrawn the effectiveness of such Registration
Statement, either temporarily or permanently, or intends or has threatened in
writing to do so. Each Registration Statement (including the information or
documents incorporated by reference therein), as of the time it was declared
effective, and any amendments or supplements thereto, each as of the time of
filing, did not contain any untrue statement of material fact or omit to state
any material fact required to be stated therein or necessary to make the
statements therein not misleading. The Company hereby agrees to file with the
SEC a prospectus supplement in accordance with the required timelines as
prescribed under Rule 424(b)(2) of the Securities Act. The issuance of the
Common Stock and Warrants to the Purchasers is registered by the Registration
Statement.

4. REPRESENTATIONS AND WARRANTIES OF EACH INVESTOR
--------------------------------------------------

         Each Investor hereby represents and warrants to the Company the
following:

         4.1 AUTHORITY. Investor has full legal right, power and capacity to
enter into, execute, deliver and perform this Agreement and all attendant
documents and instruments contemplated hereby. This Agreement has been duly
executed and delivered and constitutes the legal, valid and binding obligation
of Investor and is enforceable with respect to Investor in accordance with its
terms, except as enforcement may be limited by bankruptcy, insolvency, priority
or other laws or court decisions relating to or affecting generally the
enforcement of creditors' rights or affecting generally the availability of
equitable remedies.

                                       5
<PAGE>

         4.2 NO VIOLATION OF AGREEMENTS. Neither the execution and delivery of
this Agreement nor the consummation of the transactions contemplated hereunder
by Investor will violate or conflict with any judgment, order, decree, statute,
rule or regulation applicable to Investor or its assets or properties.

         4.3 DISCLOSURE OF INFORMATION. Subject in part to the truth and
accuracy of the representations and warranties of the Company, the Investor
believes that it has received all the information that it considers necessary or
appropriate for deciding whether to purchase the Shares and Warrants. The
Investor further represents that it has had an opportunity to review the SEC
Documents and the Form S-3 and Warrant Form S-3, and had sufficient opportunity
to ask questions and receive answers from the Company and its directors and
officers regarding the terms and conditions of the offering of the Shares and
Warrants and the business and operations of the Company. The foregoing, however,
does not limit or modify the representations and warranties of the Company in
Section 3 of this Agreement or the right of the Investor to rely thereon.

5. CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY
-----------------------------------------------------

         The obligations of the Company to consummate the transactions
contemplated by this Agreement shall be subject to the satisfaction of each of
the conditions set forth below, any or all of which may be waived by the Company
in whole or in part without prior notice; provided, however, that no such waiver
of a condition shall constitute a waiver by the Company of any other condition
or of any of the Company's rights or remedies, at law or in equity, if the
Investors shall be in default or breach of any of its representations,
warranties or agreements under this Agreement:

         5.1 PURCHASE PRICE. Each Investor shall deliver on the Closing Date
that portion of the Purchase Price to be paid by such Investor as provided in
Section 1.2.

         5.2 ACCURACY OF REPRESENTATIONS AND WARRANTIES. The representations and
warranties of each Investor contained in this Agreement shall be accurate and
complete on and as of the Closing Date with the same effect as though such
representations and warranties had been made on or as of such date.

         5.3 PERFORMANCE OF AGREEMENTS. Each and all of the conditions precedent
and agreements of the Investors subject to satisfaction on or before the Closing
Date pursuant to the terms of this Agreement shall have been performed or
satisfied.

6. CONDITIONS PRECEDENT TO OBLIGATIONS OF INVESTOR
--------------------------------------------------

         The obligations of each Investor to consummate the transactions
contemplated by this Agreement shall be subject to the satisfaction of each of
the conditions set forth below, any or all of which may be waived by each
Investor in whole or in part without prior notice; provided, however, that no
such waiver of a condition shall constitute a waiver by such Investor of any
other condition or of any of such Investor's rights or remedies, at law or in
equity, if the Company shall be in default or breach of any of its
representations, warranties or agreements under this Agreement:

                                       6
<PAGE>

         6.1 ACCURACY OF REPRESENTATIONS AND WARRANTIES. The representations and
warranties of the Company contained in this Agreement shall be accurate and
complete on and as of the Closing Date with the same effect as though such
representations and warranties had been made on or as of such date and the
Company shall have delivered to Investor a certificate to that effect signed by
the Company, and dated as of the Closing Date.

         6.2 PERFORMANCE OF AGREEMENTS. Each and all of the conditions precedent
and agreements of the Company subject to satisfaction on or before the Closing
Date pursuant to the terms of this Agreement shall have been performed or
satisfied and the Company shall have delivered to Investor a certificate to that
effect signed by the Company, and dated as of the Closing Date.

         6.3 NO ADVERSE EVENTS. Between the date hereof and the Closing Date,
neither the business, assets or condition, financial or otherwise, of the
Company taken as a whole shall have been materially adversely affected in any
manner.

         6.4 DELIVERY OF DOCUMENTS.

                  6.4.1 The Company shall have effected the transfers and
deliveries set forth in Section 1.1 and 1.3;

7. MISCELLANEOUS
----------------

         7.1 EXPENSES, COMMISSIONS AND TAXES. Each party shall bear and pay its
own expenses, including legal, accounting and other professional fees, and taxes
incurred in connection with the transactions referred to in this Agreement. The
party responsible under applicable law shall bear and pay in their entirety all
other taxes and registration and transfer fees, if any, payable by reason of the
sale and conveyance of the Shares and Warrants.

         7.2 ENTIRE AGREEMENT; MODIFICATIONS; WAIVER. This Agreement, together
with the related agreements or certificates referenced herein, constitutes the
final, exclusive and complete understanding of the parties with respect to the
subject matter hereof and supersedes any and all prior understandings and
discussions with respect thereto. No variation or modification of this Agreement
and no waiver of any provision or condition hereof, or granting of any consent
contemplated hereby, shall be valid unless in writing and signed by the party
against whom enforcement of any such variation, modification, waiver or consent
is sought.

         7.3 FURTHER ASSURANCES. The parties hereto shall use their best
efforts, and shall cooperate with one another, to secure all necessary consents,
approvals, authorizations, exemptions and waivers from third parties as shall be
required in order to consummate the transactions contemplated hereby, and shall
otherwise use their best efforts to cause such transactions to be consummated in
accordance with the terms and conditions hereof. At any time or from time to
time after the Closing Date, each party hereto, shall execute and deliver any
further instruments or documents and take all such further action as such
requesting party may reasonably request in order to consummate and document the
transactions contemplated hereby.

                                       7

<PAGE>

         7.4 CAPTIONS. The captions in this Agreement are for convenience only
and shall not be considered a part of or affect the constructing or
interpretation of any provision of this Agreement.

         7.5 SECTION REFERENCES. Unless otherwise noted, all section references
herein are to sections of this Agreement.

         7.6 COUNTERPARTS. This Agreement may be executed in any number of
counterparts, including electronically transmitted counterparts, each of which
when so executed shall constitute an original copy hereof, but all of which
together shall constitute one agreement.

         7.7 SUCCESSORS AND ASSIGNS. Neither party shall have the right to
assign this Agreement.

         7.8 PARTIES IN INTEREST. Nothing in this Agreement, whether express or
implied, is intended to confer any rights or remedies under or by reason of this
Agreement on any persons other than the parties to it and their respective
successors and assigns, nor is anything in this Agreement intended to relieve or
discharge the obligation or liability of any third persons to any party to this
Agreement, nor shall any provision give any third persons any right of
subrogation or action over against any party to this Agreement.

         7.9 NOTICES. All notices, requests, demands and other communications
hereunder ("Notices") shall be in writing and shall be deemed to have been duly
given if delivered by hand or by registered or certified mail, postage prepaid,
return receipt requested, but only upon receipt of such return receipt, as
follows:

         If to Investors:                   As noted in Exhibit I

         If to the Company:                 Peregrine Pharmaceutical, Inc.
                                            14272 Franklin Avenue, Suite 100
                                            Tustin, California 92780
                                            Attn.:  President

or to such other address as any party may have furnished to the others in
writing in accordance herewith, except that notices of change of address shall
only be effective upon receipt. All Notices shall be deemed received on the date
of delivery or, if mailed, on the date appearing on the return receipt therefor.

         7.10 LAW GOVERNING. This Agreement shall be governed by, and construed
and enforced in accordance with the laws of the State of California, without
regard to its choice-of-laws or conflicts-of-law rules.

                               [REMAINDER OF PAGE
                            INTENTIONALLY LEFT BLANK]

                                       8
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed, all as of date first above written.

                                          "The Company"
                                          Peregrine Pharmaceuticals, Inc.,
                                          a Delaware corporation

                                          BY: /S/ STEVEN W. KING
                                              ----------------------------------

                                          Name: Steven W. King

                                          Title:  President & CEO

                                       9
<PAGE>

                                   SCHEDULE I
                                 "The Investors"

Print or Type:

Name of Purchaser (Institution)             CLEVELAND OVERSEAS LTD.

Tax ID No.:                                 ____________________________________

Address (for delivery
of documents):                              C/O GTF GLOBAL TRADE & FINANCE S.A.
                                            ST. MARKUSGASSE 19
                                            FL-9490 VADUZ / LIECHTENSTEIN

DWAC
Instructions:             DTC#              ____________________________________
                          Broker            ____________________________________
                          Address           ____________________________________
                          Contact           ____________________________________
                          Phone #           ____________________________________
                          Acct Name         ____________________________________
                          Acct Number       ____________________________________

IF NO DWAC INSTRUCTIONS ARE PROVIDED, COMPANY WILL ISSUE PHYSICAL CERTIFICATE
FOR THE NUMBER OF SHARES LISTED BELOW. CERTIFICATE WILL BE MAILED TO ADDRESS
ABOVE UNLESS OTHERWISE STATED HEREIN.

Signature by:                               /s/ Gwald Vogt
                                            ------------------------------------

Name of Individual representing             Gwald Vogt - Director of
Purchaser:                                  GTF GLOBAL TRADE & FINANCE SA

NUMBER OF SHARES TO BE PURCHASED:           -27,596-

PER SHARE PURCHASE PRICE:                   $0.86

AGGREGATE PURCHASE PRICE:                   $-24,076,56-

                                       10
<PAGE>

                                   SCHEDULE I
                                 "The Investors"

Print or Type:

Name of Purchaser (Institution)             SDS MERCHANT FUND, LP

Tax ID No.:                                 ____________________________________

Address (for delivery
of documents):                              C/O SDS CAPITAL PARTNERS, LLC
                                            53 FOREST AVE., 2ND FLOOR
                                            OLD GREENWICH, CT 06870

DWAC
Instructions:             DTC#              ____________________________________
                          Broker            ____________________________________
                          Address           ____________________________________
                          Contact           ____________________________________
                          Phone #           ____________________________________
                          Acct Name         ____________________________________
                          Acct Number       ____________________________________

IF NO DWAC INSTRUCTIONS ARE PROVIDED, COMPANY WILL ISSUE PHYSICAL CERTIFICATE
FOR THE NUMBER OF SHARES LISTED BELOW. CERTIFICATE WILL BE MAILED TO ADDRESS
ABOVE UNLESS OTHERWISE STATED HEREIN.

Signature by:                               /s/ Steve Darby
                                            ------------------------------------

Name of Individual representing             Steve Darby
Purchaser:                                  MANAGING MEMBER

NUMBER OF SHARES TO BE PURCHASED:           209,967

PER SHARE PURCHASE PRICE:                   $0.86

AGGREGATE PURCHASE PRICE:                   $180,571.62

                                       11
<PAGE>

                                   SCHEDULE I
                                 "The Investors"

Print or Type:

Name of Purchaser (Institution)             OTATO, LLC

Tax ID No.:                                 ____________________________________

Address (for delivery
of documents):                              ____________________________________
                                            ____________________________________
                                            ____________________________________

DWAC
Instructions:             DTC#              ____________________________________
                          Broker            ____________________________________
                          Address           ____________________________________
                          Contact           ____________________________________
                          Phone #           ____________________________________
                          Acct Name         ____________________________________
                          Acct Number       ____________________________________

IF NO DWAC INSTRUCTIONS ARE PROVIDED, COMPANY WILL ISSUE PHYSICAL CERTIFICATE
FOR THE NUMBER OF SHARES LISTED BELOW. CERTIFICATE WILL BE MAILED TO ADDRESS
ABOVE UNLESS OTHERWISE STATED HEREIN.

Signature by:                               /s/ Richard M. Cayne
                                            ------------------------------------

Name of Individual representing
Purchaser:                                  RICHARD M. CAYNE

NUMBER OF SHARES TO BE PURCHASED:           111,983

PER SHARE PURCHASE PRICE:                   $0.86

AGGREGATE PURCHASE PRICE:                   $96,305.38

                                       12
<PAGE>

                                   SCHEDULE I
                                 "The Investors"

Print or Type:

Name of Purchaser (Institution)             CRANSHIRE CAPITAL, L.P.

Tax ID No.:                                 ____________________________________

Address (for delivery
of documents):                              666 DUNDEE RD., SUITE 1901
                                            NORTHBROOK, IL 60062
                                            ____________________________________

DWAC
Instructions:             DTC#              ____________________________________
                          Broker            ____________________________________
                          Address           ____________________________________
                          Contact           ____________________________________
                          Phone #           ____________________________________
                          Acct Name         ____________________________________
                          Acct Number       ____________________________________

IF NO DWAC INSTRUCTIONS ARE PROVIDED, COMPANY WILL ISSUE PHYSICAL CERTIFICATE
FOR THE NUMBER OF SHARES LISTED BELOW. CERTIFICATE WILL BE MAILED TO ADDRESS
ABOVE UNLESS OTHERWISE STATED HEREIN.

Signature by:                               /s/ Mitchell P. Kopin
                                            ------------------------------------

Name of Individual representing
Purchaser:                                  MITCHELL P. KOPIN

NUMBER OF SHARES TO BE PURCHASED:           251,960

PER SHARE PURCHASE PRICE:                   $0.86

AGGREGATE PURCHASE PRICE:                   $216,685.60

                                       13
<PAGE>

                                   SCHEDULE I
                                 "The Investors"

Print or Type:

Name of Purchaser (Institution)             ZLP MASTER TECHNOLOGY FUND, LTD.

Tax ID No.:                                 ____________________________________

Address (for delivery
of documents):                              45 BROADWAY, 28TH FLOOR
                                            NEW YORK, NY 10006
                                            ____________________________________

DWAC
Instructions:             DTC#              ____________________________________
                          Broker            ____________________________________
                          Address           ____________________________________
                          Contact           ____________________________________
                          Phone #           ____________________________________
                          Acct Name         ____________________________________
                          Acct Number       ____________________________________

IF NO DWAC INSTRUCTIONS ARE PROVIDED, COMPANY WILL ISSUE PHYSICAL CERTIFICATE
FOR THE NUMBER OF SHARES LISTED BELOW. CERTIFICATE WILL BE MAILED TO ADDRESS
ABOVE UNLESS OTHERWISE STATED HEREIN.

Signature by:                               /s/ Stuart J. Zimmer
                                            ------------------------------------

Name of Individual representing
Purchaser:                                  STUART J. ZIMMER

NUMBER OF SHARES TO BE PURCHASED:           600,224

PER SHARE PURCHASE PRICE:                   $0.86

AGGREGATE PURCHASE PRICE:                   $516,192.64

                                       14
<PAGE>

                                   SCHEDULE I
                                 "The Investors"

Print or Type:

Name of Purchaser (Institution)             ALPHA CAPITAL AG

Tax ID No.:                                 ____________________________________

Address (for delivery
of documents):                              L.H. FINANCIAL
                                            160 CENTRAL PARK SOUTH
                                            NEW YORK, NY 10019

DWAC
Instructions:             DTC#              ____________________________________
                          Broker            ____________________________________
                          Address           ____________________________________
                          Contact           ____________________________________
                          Phone #           ____________________________________
                          Acct Name         ____________________________________
                          Acct Number       ____________________________________

IF NO DWAC INSTRUCTIONS ARE PROVIDED, COMPANY WILL ISSUE PHYSICAL CERTIFICATE
FOR THE NUMBER OF SHARES LISTED BELOW. CERTIFICATE WILL BE MAILED TO ADDRESS
ABOVE UNLESS OTHERWISE STATED HEREIN.

Signature by:                               /s/ Konrad Ackerman
                                            ------------------------------------

Name of Individual representing
Purchaser:                                  KONRAD ACKERMAN

NUMBER OF SHARES TO BE PURCHASED:           97,985

PER SHARE PURCHASE PRICE:                   $0.86

AGGREGATE PURCHASE PRICE:                   $84,267.10

                                       15
<PAGE>

                                   SCHEDULE I
                                 "The Investors"

Print or Type:

Name of Purchaser (Institution)             XMARK FUNDS, L.P.

Tax ID No.:                                 ____________________________________

Address (for delivery
of documents):                              152 WEST 57TH ST., 21ST FLOOR
                                            NEW YORK, NY 10019
                                            ____________________________________

DWAC
Instructions:             DTC#              ____________________________________
                          Broker            ____________________________________
                          Address           ____________________________________
                          Contact           ____________________________________
                          Phone #           ____________________________________
                          Acct Name         ____________________________________
                          Acct Number       ____________________________________

IF NO DWAC INSTRUCTIONS ARE PROVIDED, COMPANY WILL ISSUE PHYSICAL CERTIFICATE
FOR THE NUMBER OF SHARES LISTED BELOW. CERTIFICATE WILL BE MAILED TO ADDRESS
ABOVE UNLESS OTHERWISE STATED HEREIN.

Signature by:                               /s/ Mitchell D. Kaye
                                            ------------------------------------

Name of Individual representing
Purchaser:                                  MITCHELL D. KAYE

NUMBER OF SHARES TO BE PURCHASED:           279,955

PER SHARE PURCHASE PRICE:                   $0.86

AGGREGATE PURCHASE PRICE:                   $240,762

                                       16
<PAGE>

                                   SCHEDULE I
                                 "The Investors"

Print or Type:

Name of Purchaser (Institution)             XMARK FUNDS, LTD.

Tax ID No.:                                 ____________________________________

Address (for delivery
of documents):                              152 WEST 57TH ST., 21ST FLOOR
                                            NEW YORK, NY 10019
                                            ____________________________________

DWAC
Instructions:             DTC#              ____________________________________
                          Broker            ____________________________________
                          Address           ____________________________________
                          Contact           ____________________________________
                          Phone #           ____________________________________
                          Acct Name         ____________________________________
                          Acct Number       ____________________________________

IF NO DWAC INSTRUCTIONS ARE PROVIDED, COMPANY WILL ISSUE PHYSICAL CERTIFICATE
FOR THE NUMBER OF SHARES LISTED BELOW. CERTIFICATE WILL BE MAILED TO ADDRESS
ABOVE UNLESS OTHERWISE STATED HEREIN.

Signature by:                               /s/ Mitchell D. Kaye
                                            ------------------------------------

Name of Individual representing
Purchaser:                                  MITCHELL D. KAYE

NUMBER OF SHARES TO BE PURCHASED:           419,933

PER SHARE PURCHASE PRICE:                   $0.86

AGGREGATE PURCHASE PRICE:                   $361,143

                                       17
<PAGE>

                                  SCHEDULE 3.5

                                   LITIGATION

None

<PAGE>

                                   Schedule A
                              Fees and Commissions

1.Olympus Securities - 5% of the gross proceeds received by the Company from the
following nine (9) investors as more fully described in the Finders Agreement
dated August 8, 2002:

          1.       Vertical Ventures, LLC and affiliates
          2.       Cleveland Overseas Ltd. and affiliates
          3.       Xmark and affiliates
          4.       SDS Capital and affiliates
          5.       Alpha Capital and affiliates
          6.       Cranshire Capital and affiliates
          7.       West End Capital and affiliates
          8.       OTA and affiliates
          9.       Zimmer Lucas and affiliates

                                       19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]